Start-Up Previews (01/2011)
A preview of the emerging health companies profiled in the current issue of Start-Up. This month's profile group, "Benlysta May Lead Wave Of New Approvals For Lupus Drugs," features profiles of Azano Pharmaceuticals, Resolve Therapeutics and SuppreMol. Plus these Start-Ups Across Health Care: biocrea, e(ye)BRAIN, MiCardia and Omthera Pharmaceuticals
You may also be interested in...
Patients requiring mitral valve repair of the heart to reduce recurrent leakage of blood or residual regurgitation after initial implant can now avoid going under the knife for a second time. MiCardia's Dynaplasty platform has been designed to change the shape of an implantable medical device in response to fluctuations in anatomical conditions. For mitral valve repair, MiCardia's shape-memory nitinol device is similar to a standard annuloplasty ring, but when activated, pulls the two leaflets together in such a fashion as to significantly minimize regurgitation.
Could the eyes hold the key to diagnosing neurologic conditions by associating eye movement behavior to specific areas of the brain? French start-up e(ye)BRAIN certainly thinks so, and as a result has developed a brain tracking medical device that its inventor claims is able to diagnose Parkinson's disease and multiple sclerosis.
SuppreMol GMBH is developing a recombinant version of human Fcy receptor FcyRIIb, now in Phase IIa for SLE. This candidate competes with membrane-bound Fcy receptors on immune cells, preventing binding of immune complexes containing autoantigens and inhibiting re-stimulation of immune cells. This down-regulates the B cells specifically involved in the autoimmune response, but does not affect B cells that are part of the normal immune response.